U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07906561) titled 'Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis' on Oct. 19.
Brief Summary: The purpose of this study is to find out whether blood levels of two proteins, GDF-15 and LGALS3BP, measured at intensive care unit admission and at 72 hours, can help predict survival and organ dysfunction in adult patients with sepsis or septic shock. Blood samples are collected together with routine laboratory tests, without additional needle sticks. The study does not change patient treatment.
Study Start Date: Nov., 2026
Study Type: OBSERVATIONAL
Condition:
Sepsis
Septic Shock
Intervention:
DIAGNOSTIC_TEST: Serum GDF-15 and LGALS3BP M...